SCHEMBL9913545

SCHEMBL9913545

CC(C)(C)OC(=O)NCc1ccccc1C(O)c1ccc2[nH]ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.40
KCNA5 P22460 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
NR3C1 P04150 1/20 0.38
BCHE P06276 1/20 0.36
NQO2 P16083 1/20 0.36
CYP1A2 P05177 1/20 0.36
PTGS2 P35354 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
NOTUM Q6P988 1/20 0.35
ACACB O00763 1/20 0.35
C5AR1 P21730 1/20 0.34
TACR1 P25103 1/20 0.34
CTNNB1 P35222 2/20 0.34
WNT3A P56704 2/20 0.34
EPHX2 P34913 1/20 0.34
PPARG P37231 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13539191 0.90 KDM4A (0.43) KDM4AKCNA5SLC6A2SLC6A4SLC6A3
SCHEMBL9914916 0.85 SLC6A2 (0.38) SLC6A2SLC6A4SLC6A3NR3C1PTGS2
SCHEMBL3180280 0.81 SLC6A2 (0.52) SLC6A2SLC6A4SLC6A3NR3C1PTGS2
SCHEMBL2307317 0.78 SLC6A2 (0.53) KDM4ASLC6A2SLC6A4SLC6A3NR3C1
SCHEMBL29792562 0.76 L3MBTL1 (0.49) KDM4AMAPT
SCHEMBL7214903 0.76 L3MBTL1 (0.49) KDM4AMAPT
SCHEMBL31444360 0.74 KCNA5 (0.47) KDM4AKCNA5NPC1RAB9A
SCHEMBL17447242 0.73 GPR84 (0.42) KDM4AKCNA5BCHENQO2CYP1A2
SCHEMBL12743180 0.73 KCNA5 (0.55) KDM4AKCNA5NQO2MAPT
SCHEMBL17018470 0.72 KCNA5 (0.52) KDM4AKCNA5BCHENQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198274-B2 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2012-06-12 US disclosed
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof ROCHE PALO ALTO LLC 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016312-A1 Substituted indolyl and indazolyl derivatives and uses thereof MAOB, MAOA, TPH1 KDM4A 1175/4885KCNA5 572/4885SLC6A2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.